Suppr超能文献

一种用于评估基于脂质的制剂中药物吸收机制的新型体外脂质消化-体内吸收模型。

A new in vitro lipid digestion - in vivo absorption model to evaluate the mechanisms of drug absorption from lipid-based formulations.

作者信息

Crum Matthew F, Trevaskis Natalie L, Williams Hywel D, Pouton Colin W, Porter Christopher J H

机构信息

Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia.

Capsugel R&D Australia, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia.

出版信息

Pharm Res. 2016 Apr;33(4):970-82. doi: 10.1007/s11095-015-1843-7. Epub 2015 Dec 24.

Abstract

PURPOSE

In vitro lipid digestion models are commonly used to screen lipid-based formulations (LBF), but in vitro-in vivo correlations are in some cases unsuccessful. Here we enhance the scope of the lipid digestion test by incorporating an absorption 'sink' into the experimental model.

METHODS

An in vitro model of lipid digestion was coupled directly to a single pass in situ intestinal perfusion experiment in an anaesthetised rat. The model allowed simultaneous real-time analysis of the digestion and absorption of LBFs of fenofibrate and was employed to evaluate the influence of formulation digestion, supersaturation and precipitation on drug absorption.

RESULTS

Formulations containing higher quantities of co-solvent and surfactant resulted in higher supersaturation and more rapid drug precipitation in vitro when compared to those containing higher quantities of lipid. In contrast, when the same formulations were examined using the coupled in vitro lipid digestion - in vivo absorption model, drug flux into the mesenteric vein was similar regardless of in vitro formulation performance.

CONCLUSION

For some drugs, simple in vitro lipid digestion models may underestimate the potential for absorption from LBFs. Consistent with recent in vivo studies, drug absorption for rapidly absorbed drugs such as fenofibrate may occur even when drug precipitation is apparent during in vitro digestion.

摘要

目的

体外脂质消化模型常用于筛选基于脂质的制剂(LBF),但在某些情况下体外-体内相关性并不成功。在此,我们通过将吸收“汇”纳入实验模型来扩大脂质消化试验的范围。

方法

脂质消化的体外模型直接与麻醉大鼠的单次原位肠道灌注实验相结合。该模型允许同时实时分析非诺贝特LBF的消化和吸收,并用于评估制剂消化、过饱和和沉淀对药物吸收的影响。

结果

与含有较高量脂质的制剂相比,含有较高量助溶剂和表面活性剂的制剂在体外导致更高的过饱和度和更快的药物沉淀。相比之下,当使用体外脂质消化-体内吸收耦合模型检查相同制剂时,无论体外制剂性能如何,进入肠系膜静脉的药物通量相似。

结论

对于某些药物,简单的体外脂质消化模型可能低估了从LBF吸收的潜力。与最近的体内研究一致,即使在体外消化过程中药物沉淀明显,非诺贝特等快速吸收药物的药物吸收仍可能发生。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验